AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35553901 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono‐unsaturated fatty acids
Number of subjects: 192
Study 35553901 — intervention group
Group type: EXPERIMENTAL
Intervention: Total saturated fatty acids
Number of subjects: 192
Study 32045259 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus antihypertensive drugs
Number of subjects: 70
Study 32045259 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drugs only (Control)
Number of subjects: 70
Study 35714267 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency neurolysis (TCRF) of the posterior nasal nerve (PNN) area
Number of subjects: 77
Study 35714267 — intervention group
Group type: COMPARATOR
Intervention: Crossover to active treatment from sham-control
Number of subjects: 77
Study 33537902 — intervention group
Group type: EXPERIMENTAL
Intervention: Kerr Life (KL)
Number of subjects: 42
Study 33537902 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM zinc oxide eugenol cement (IRM)
Number of subjects: 42
Study 33537902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Bond (KB)
Number of subjects: 42
Study 33537902 — intervention group
Group type: EXPERIMENTAL
Intervention: Dycal (DY)
Number of subjects: 42
Study 33537902 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrebond (VB)
Number of subjects: 42
Study 33537902 — intervention group
Group type: EXPERIMENTAL
Intervention: mineral trioxide aggregate (MTA)
Number of subjects: 42
Study 33537902 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond NT (PB)
Number of subjects: 42
Study 33537902 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 42
Study 33203003 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (100 mg/day) and exercise
Number of subjects: 31
Study 33203003 — intervention group
Group type: COMPARATOR
Intervention: Placebo and exercise
Number of subjects: 31
Study 35815739 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 PUFA supplementation (1020 mg daily for 12 weeks)
Number of subjects: 40
Study 35815739 — intervention group
Group type: COMPARATOR
Intervention: Control group (weight loss diet only)
Number of subjects: 40
Study 35815739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (omega-3 and control)
Number of subjects: 40
Study 32566763 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 361
Study 32566763 — intervention group
Group type: COMPARATOR
Intervention: waiting-list
Number of subjects: 361
Study 36129139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Map group
Number of subjects: 45
Study 36129139 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 45
Study 33857891 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in the number of grain boundaries from 3 to 25
Number of subjects: 0
Study 33857891 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in crack length
Number of subjects: 0
Study 32059855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hemoadsorption
Number of subjects: 58
Study 32059855 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery without hemoadsorption)
Number of subjects: 58
Study 35584336 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacestrant 400 mg orally once daily
Number of subjects: 477
Study 35584336 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) endocrine monotherapy
Number of subjects: 477
Study 32768551 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) plus usual care
Number of subjects: 30
Study 32768551 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 30
Study 32768551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EA and control)
Number of subjects: 30
Study 32706667 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT combined with serious gaming for 6 weeks
Number of subjects: 69
Study 32706667 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 69
Study 36401521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanolin treatment
Number of subjects: 206
Study 36401521 — intervention group
Group type: COMPARATOR
Intervention: Human milk treatment
Number of subjects: 206
Study 35367282 — intervention group
Group type: EXPERIMENTAL
Intervention: Seladelpar 2 mg/day
Number of subjects: 119
Study 35367282 — intervention group
Group type: EXPERIMENTAL
Intervention: Seladelpar 5 mg/day
Number of subjects: 119
Study 35367282 — intervention group
Group type: EXPERIMENTAL
Intervention: Seladelpar 10 mg/day
Number of subjects: 119
Study 35367282 — intervention group
Group type: EXPERIMENTAL
Intervention: Seladelpar 5 mg/day and 10 mg/day
Number of subjects: 119
Study 35367282 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 119
Study 32183815 — intervention group
Group type: EXPERIMENTAL
Intervention: Park Prescription Intervention (PPI): Face-to-face Park Prescription + invitation to weekly exercise sessions in parks
Number of subjects: 160
Study 34046921 — intervention group
Group type: EXPERIMENTAL
Intervention: STR-324 (0.004-11.475 mg h-1)
Number of subjects: 78
Study 34046921 — intervention group
Group type: EXPERIMENTAL
Intervention: STR-324 (1.25-11.25 mg h-1)
Number of subjects: 78
Study 34046921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 33252584 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 centistoke silicone oil tamponade
Number of subjects: 302
Study 33252584 — intervention group
Group type: COMPARATOR
Intervention: 14% to 16% silicone oil to perfluoropropane gas tamponade
Number of subjects: 302
Study 32921466 — intervention group
Group type: EXPERIMENTAL
Intervention: 22AA milk replacer (MR) with greater EAA concentrations (24% CP) fed at 0.57 kg/d for 0-14 d, increased to 0.85 kg/d through 35 d, then 0.41 kg/d until weaning after 42 d.
Number of subjects: 40
Study 32921466 — intervention group
Group type: COMPARATOR
Intervention: 22CP milk replacer (MR) (standard 22:20 CP:fat) fed at 0.57 kg/d for 0-14 d, increased to 0.85 kg/d through 35 d, then 0.41 kg/d until weaning after 42 d.
Number of subjects: 40
Study 32921466 — intervention group
Group type: EXPERIMENTAL
Intervention: 22AA milk replacer (MR)
Number of subjects: 40
Study 32921466 — intervention group
Group type: COMPARATOR
Intervention: 22CP milk replacer (MR)
Number of subjects: 40
Study 32279536 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual bootstrap with studentized CI
Number of subjects: 0
Study 32279536 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual bootstrap with basic CI
Number of subjects: 0
Study 32279536 — intervention group
Group type: COMPARATOR
Intervention: Analytic methods
Number of subjects: 0
Study 36218094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of carboprost combined with oxytocin (20IU oxytocin and small pot drip of 10IU oxytocin after delivery)
Number of subjects: 180
Study 36218094 — intervention group
Group type: COMPARATOR
Intervention: 1mg of carboprost when the fetal head came out and then intramuscular injection of 20IU oxytocin
Number of subjects: 180
Study 33983840 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum during mechanical ventilation
Number of subjects: 0
Study 33983840 — intervention group
Group type: COMPARATOR
Intervention: Control group (colostrum only for gastrointestinal nutrition)
Number of subjects: 0
Study 32430987 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure drainage assisted irrigation (NPDI)
Number of subjects: 58
Study 32430987 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 58
Study 33429093 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Water (TW) group
Number of subjects: 34
Study 33429093 — intervention group
Group type: COMPARATOR
Intervention: Dryland (DL) group
Number of subjects: 34
Study 32668036 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic treatment with post-installation at the first visit (group 1)
Number of subjects: 100
Study 32668036 — intervention group
Group type: COMPARATOR
Intervention: Endodontic treatment with post-installation at the second visit (group 2)
Number of subjects: 100
Study 32668036 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 100
Study 35821134 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-step etch-and-rinse (3-ER)
Number of subjects: 39
Study 35821134 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step etch-and-rinse (2-ER)
Number of subjects: 39
Study 35821134 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step self-etch (2-SE)
Number of subjects: 39
Study 35821134 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step self-etch (1-SE)
Number of subjects: 39
Study 36495881 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks
Number of subjects: 400
Study 36495881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 32854568 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 250 µg
Number of subjects: 18
Study 32854568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 32544854 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive memory span training (20 sessions)
Number of subjects: 60
Study 32544854 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive easy version of memory span task (20 sessions)
Number of subjects: 60
Study 32544854 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects carrying the non-risk allele (C) of rs1344706
Number of subjects: 60
Study 35960160 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 35960160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34234540 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training (ProT)
Number of subjects: 42
Study 34234540 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniocervical flexor training (CCFT)
Number of subjects: 42
Study 35977951 — intervention group
Group type: COMPARATOR
Intervention: placebo (relaxing music)
Number of subjects: 89
Study 35977951 — intervention group
Group type: EXPERIMENTAL
Intervention: tinnitus retraining therapy
Number of subjects: 89
Study 35977951 — intervention group
Group type: EXPERIMENTAL
Intervention: auditory discrimination therapy
Number of subjects: 89
Study 35977951 — intervention group
Group type: EXPERIMENTAL
Intervention: enriched acoustic environment
Number of subjects: 89
Study 35977951 — intervention group
Group type: EXPERIMENTAL
Intervention: binaural beats therapy
Number of subjects: 89
Study 33684925 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with chemotherapy
Number of subjects: 68
Study 34347918 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV maintained at 7-10%
Number of subjects: 54
Study 34347918 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV maintained at 3-6%
Number of subjects: 54
Study 33010438 — intervention group
Group type: EXPERIMENTAL
Intervention: 135° humeral inclination
Number of subjects: 14
Study 33010438 — intervention group
Group type: COMPARATOR
Intervention: 155° humeral inclination
Number of subjects: 14
Study 32899902 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive stretching of respiratory muscles after a hot pack
Number of subjects: 30
Study 32899902 — intervention group
Group type: COMPARATOR
Intervention: Control group received a hot pack followed by relaxed passive movements of the shoulder joints
Number of subjects: 30
Study 32899902 — intervention group
Group type: COMPARATOR
Intervention: Comparison between experimental and control groups
Number of subjects: 30
Study 35597286 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-guided self-prone positioning intervention
Number of subjects: 293
Study 35597286 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 293
Study 32613250 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear aligners
Number of subjects: 110
Study 32613250 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliances
Number of subjects: 110
Study 34896568 — intervention group
Group type: COMPARATOR
Intervention: RE+control (EX+CON)
Number of subjects: 36
Study 34896568 — intervention group
Group type: COMPARATOR
Intervention: RE+whey protein (EX+PRO)
Number of subjects: 36
Study 34896568 — intervention group
Group type: COMPARATOR
Intervention: RE (EX+CON and EX+PRO pooled)
Number of subjects: 36
Study 34896568 — intervention group
Group type: COMPARATOR
Intervention: Whey protein supplementation (PRO and EX+PRO pooled)
Number of subjects: 36
Study 34175959 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction (VR‐D)
Number of subjects: 50
Study 33112250 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based monitoring (26% of hospitals, 19/73)
Number of subjects: 57
Study 33112250 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (23% of hospitals, 17/73)
Number of subjects: 57
Study 33112250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both home-based monitoring and telemonitoring (11% of hospitals, 8/73)
Number of subjects: 57
Study 33112250 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (2009-2018)
Number of subjects: 57
Study 33112250 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring centers (17 centers)
Number of subjects: 57
Study 33112250 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (6/17 centers)
Number of subjects: 57
Study 33112250 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based monitoring and telemonitoring
Number of subjects: 57
Study 32185992 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 105
Study 32185992 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine
Number of subjects: 105
Study 32185992 — intervention group
Group type: COMPARATOR
Intervention: Chinese patent medicine
Number of subjects: 105
Study 35139274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy group
Number of subjects: 1174
Study 35139274 — intervention group
Group type: COMPARATOR
Intervention: Placebo-chemotherapy group
Number of subjects: 1174
Study 33251650 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sirolimus 0.2% cream plus Pulsed Dye Laser (PDL)
Number of subjects: 15
Study 33251650 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Dye Laser (PDL) plus placebo
Number of subjects: 15
Study 33593770 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunisation
Number of subjects: 300
Study 33593770 — intervention group
Group type: COMPARATOR
Intervention: No BCG immunisation
Number of subjects: 300
Study 32227216 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (maximum dosage of 300 mg for 13 weeks)
Number of subjects: 34
Study 32227216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 32227216 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 34
Study 34524150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed RM, adaptive (experimental group)
Number of subjects: 57
Study 34524150 — intervention group
Group type: COMPARATOR
Intervention: Cogmed RM, nonadaptive (active control group)
Number of subjects: 57
Study 34062731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD) intervention including sourdough bread, chickpeas/hummus, nuts, and pomegranate juice
Number of subjects: 240
Study 34062731 — intervention group
Group type: COMPARATOR
Intervention: Traditional low-fat diet intervention
Number of subjects: 240
Study 32452118 — intervention group
Group type: EXPERIMENTAL
Intervention: Isorhamnetin administered orally for 21 consecutive days
Number of subjects: 0
Study 32452118 — intervention group
Group type: EXPERIMENTAL
Intervention: Isorhamnetin
Number of subjects: 0
Study 32452118 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil administered orally for 21 consecutive days
Number of subjects: 0
Study 34463762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT)
Number of subjects: 56
Study 34463762 — intervention group
Group type: COMPARATOR
Intervention: Time in Bed Regularization (TBR)
Number of subjects: 56
Study 32539534 — intervention group
Group type: EXPERIMENTAL
Intervention: VCCV tokens categorized into VCuCV and VCiCV categories
Number of subjects: 0
Study 32539534 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination of VCCV tokens from VCuCV and VCiCV tokens
Number of subjects: 0
Study 32444166 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reappraisal coping intervention (PRCI)
Number of subjects: 75
Study 32444166 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaires only)
Number of subjects: 75
Study 36445774 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA/PGA + rhBMP-2
Number of subjects: 24
Study 36445774 — intervention group
Group type: COMPARATOR
Intervention: PLA/PGA alone
Number of subjects: 24
Study 32945055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS), 1800 pulses/session, ten daily sessions
Number of subjects: 50
Study 32945055 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 50
Study 32307654 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (immune checkpoint inhibitors)
Number of subjects: 0
Study 32307654 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33917165 — intervention group
Group type: EXPERIMENTAL
Intervention: Green leafy vegetables (GLV) intervention, 1 cooked cup equivalent daily for 4 weeks
Number of subjects: 50
Study 32740290 — intervention group
Group type: EXPERIMENTAL
Intervention: Wathen1RM
Number of subjects: 20
Study 32740290 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayhew1RM
Number of subjects: 20
Study 32740290 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV1RM
Number of subjects: 20
Study 32740290 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley1RM
Number of subjects: 20
Study 32740290 — intervention group
Group type: EXPERIMENTAL
Intervention: RTF1RM
Number of subjects: 20
Study 34475255 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment for acute ischemic stroke (AIS)
Number of subjects: 277
Study 33530034 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with late-onset preeclampsia (DPE)
Number of subjects: 213
Study 33530034 — intervention group
Group type: COMPARATOR
Intervention: Women without late-onset preeclampsia (controls)
Number of subjects: 213
Study 32122621 — intervention group
Group type: EXPERIMENTAL
Intervention: Recession and plication (RP)
Number of subjects: 60
Study 32122621 — intervention group
Group type: COMPARATOR
Intervention: Recession and resection (RR)
Number of subjects: 60
Study 35960487 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg
Number of subjects: 1688
Study 35960487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1688
Study 35960487 — intervention group
Group type: COMPARATOR
Intervention: Apremilast
Number of subjects: 1688
Study 33524489 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal protective equipment without valve
Number of subjects: 48
Study 33524489 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal protective equipment with valve
Number of subjects: 48
Study 33524489 — intervention group
Group type: COMPARATOR
Intervention: Control (no personal protective equipment)
Number of subjects: 48
Study 36098968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3, 2000 IU/d
Number of subjects: 25871
Study 36098968 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids, 1 g/d
Number of subjects: 25871
Study 36098968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25871
Study 35691183 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (10 g)
Number of subjects: 30
Study 35691183 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g)
Number of subjects: 30
Study 33308291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D)
Number of subjects: 600
Study 33308291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 35798473 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stent approach
Number of subjects: 653
Study 35798473 — intervention group
Group type: COMPARATOR
Intervention: Provisional Stenting (PS)
Number of subjects: 653
Study 34555839 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cetirizine 10 mg
Number of subjects: 34
Study 34555839 — intervention group
Group type: COMPARATOR
Intervention: IV diphenhydramine 50 mg
Number of subjects: 34
Study 35149037 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 289
Study 35149037 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 289
Study 33143369 — intervention group
Group type: EXPERIMENTAL
Intervention: fortified sachet with Ca+VitD and milk plus early PT
Number of subjects: 69
Study 33143369 — intervention group
Group type: COMPARATOR
Intervention: placebo and milk plus early PT
Number of subjects: 69
Study 33143369 — intervention group
Group type: EXPERIMENTAL
Intervention: fortified sachet with Ca+VitD and milk plus late PT after childbirth
Number of subjects: 69
Study 33143369 — intervention group
Group type: COMPARATOR
Intervention: placebo and milk plus late PT
Number of subjects: 69
Study 34054072 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid and femoral Doppler ultrasound (DUS) in RA patients
Number of subjects: 35
Study 34054072 — intervention group
Group type: COMPARATOR
Intervention: Carotid and femoral Doppler ultrasound (DUS) in control group
Number of subjects: 35
Study 34054072 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid DUS in RA patients
Number of subjects: 35
Study 34054072 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral DUS in RA patients
Number of subjects: 35
Study 34054072 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid and femoral DUS after EULAR 1.5 multiplication factor in RA patients
Number of subjects: 35
Study 32164646 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage screening procedure (first-stage via school setting, second-stage with fasting plasma glucose and blood pressure measurements)
Number of subjects: 3153
Study 32164646 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage screening procedure
Number of subjects: 3153
Study 35854360 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluoroquinolone or trimethoprim-sulfamethoxazole
Number of subjects: 720